Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Acquired by GAMMA Investing LLC

GAMMA Investing LLC lifted its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 8,947.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,552 shares of the specialty pharmaceutical company's stock after acquiring an additional 17,358 shares during the period. GAMMA Investing LLC owned 0.05% of Collegium Pharmaceutical worth $524,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of COLL. Invesco Ltd. grew its position in shares of Collegium Pharmaceutical by 19.5% during the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock worth $50,876,000 after acquiring an additional 289,335 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of Collegium Pharmaceutical by 319.4% during the fourth quarter. Janus Henderson Group PLC now owns 291,388 shares of the specialty pharmaceutical company's stock worth $8,341,000 after acquiring an additional 221,903 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Collegium Pharmaceutical during the fourth quarter worth approximately $3,489,000. Raymond James Financial Inc. purchased a new position in shares of Collegium Pharmaceutical during the fourth quarter worth approximately $2,432,000. Finally, F M Investments LLC purchased a new position in shares of Collegium Pharmaceutical during the fourth quarter worth approximately $2,096,000.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Piper Sandler restated a "neutral" rating and set a $37.00 target price (up from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. HC Wainwright reiterated a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Needham & Company LLC reiterated a "buy" rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. Finally, Wall Street Zen upgraded shares of Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research report on Saturday. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $43.75.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL traded up $0.23 during midday trading on Friday, reaching $29.83. The stock had a trading volume of 669,952 shares, compared to its average volume of 405,163. The firm has a fifty day simple moving average of $28.57 and a two-hundred day simple moving average of $29.52. Collegium Pharmaceutical, Inc. has a 12-month low of $23.23 and a 12-month high of $42.29. The company has a quick ratio of 1.01, a current ratio of 1.08 and a debt-to-equity ratio of 3.30. The stock has a market cap of $958.44 million, a P/E ratio of 24.45 and a beta of 0.63.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing analysts' consensus estimates of $1.50 by ($0.01). The firm had revenue of $177.76 million during the quarter, compared to analysts' expectations of $174.96 million. Collegium Pharmaceutical had a net margin of 6.61% and a return on equity of 99.08%. The business's quarterly revenue was up 22.7% on a year-over-year basis. During the same quarter last year, the business earned $1.45 earnings per share. On average, equities analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, Director John Gordon Freund sold 6,601 shares of the business's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $30.62, for a total transaction of $202,122.62. Following the sale, the director now directly owns 70,658 shares in the company, valued at approximately $2,163,547.96. The trade was a 8.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.